# ANGLE plc

ANGLE plc is an Asset Manager based in Guildford, United Kingdom.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Guildford, United Kingdom
- **Region:** Europe
- **Address:** Guildford, Surrey, United Kingdom
- **Founded:** 1996
- **Assets under management:** Undisclosed
- **Website:** angleplc.com

## Regulatory record

- **Reports private funds:** No

## About

ANGLE plc was founded in 1996 by Andrew Newland in Guildford, England, as an R&D company focused on developing a platform to harvest circulating tumor cells from blood samples. The company listed on the AIM market of the London Stock Exchange in 2004 (ticker: AGL) and now employs approximately 100 people across its UK headquarters and a US subsidiary in Pennsylvania. The Parsortix system is the firm's core technology — a microfluidic device that captures intact tumor cells from a blood sample without labels. ANGLE has built a proprietary workflow for downstream genomic and protein analysis of those cells, targeting applications in cancer diagnosis, treatment selection, and therapy monitoring. The firm has pursued US Food and Drug Administration clearance, receiving a Breakthrough Device Designation in 2019; a pivotal clinical trial for FDA clearance was completed in 2022. Revenue is generated through instrument sales, consumable kits, and services provided to pharmaceutical companies and academic researchers. As of 2025, ANGLE had placed over 500 Parsortix instruments globally, primarily in research labs. The company has reported accumulated losses since inception, typical of a diagnostics development company at this stage. In 2023, the firm raised £12.2 million via a share placing to fund its clinical and regulatory pathway. ANGLE's structural differentiator is its focus on a specific liquid biopsy technology — CTC capture rather than the commonly targeted circulating tumor DNA — and its pursuit of FDA clearance as a class II medical device. The business model combines hardware, consumables, and clinical service revenue, which is rare among diagnostic developers targeting the same indication.

## Sectors

- Healthcare Services
- Diagnostics
- Life Sciences Tools & Services

## People

- Andrew Newland — Founder and Chief Executive Officer
- Robyn Barter — Chief Financial Officer
- Steve Young — Chairman

## Questions

### How is ANGLE plc structured as a company?

ANGLE is a public limited company (plc) listed on the AIM market of the London Stock Exchange under ticker AGL. It operates as a single corporate entity with a UK headquarters in Guildford and a US subsidiary for American commercial operations.

### What is the Parsortix system's competitive advantage over other liquid biopsy approaches?

Most liquid biopsy tests target circulating tumor DNA (ctDNA) in blood plasma. Parsortix instead captures intact circulating tumor cells (CTCs), enabling downstream analysis of proteins and whole-cell morphology, which provides complementary information to ctDNA tests.

### Has ANGLE plc conducted any significant clinical trials?

Yes, ANGLE has run multiple clinical trials in collaboration with pharmaceutical partners and academic centers, including studies in metastatic breast cancer, prostate cancer, and lung cancer. The pivotal clinical trial for FDA clearance used samples from breast cancer patients and was completed in 2022.

### Who are the key pharmaceutical partners for ANGLE plc?

ANGLE has disclosed collaborations with multiple pharmaceutical companies, though specific named partners are not consistently public. The firm's strategy involves working with drug developers to incorporate Parsortix into clinical trials for patient stratification and therapy monitoring.

## Related profiles

- [Bio Essence Corp](https://altss.com/profile/bio-essence-corp)
- [Salem Media Group](https://altss.com/profile/salem-media-group-inc-de)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/angle-plc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology